Tenderwize
Zurück zur Suche

Open House Original Rebate Contracts 2025-05 - Emtricitabine/Tenofovir Disoproxil/Rilpivirine (Active Combination)

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 187 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-05 - Emtricitabin/Tenofovirdisoproxil/Rilpivirin (Wirkstoffkombination)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

30 / 100

Risikofaktoren

Patent expiry or loss of market exclusivity automatically terminates the contract for the affected drug. This may resul...

No guaranteed sales volume or revenue; the rebate contract does not ensure actual prescriptions or market share.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Conclude rebate contracts for the drug combination Emtricitabine/Tenofovir Disoproxil/Rilpivirine
  • No individual negotiations; standard terms apply
Vollständige Zusammenfassung anzeigen

This is an Open House procedure (not a public procurement) by Techniker Krankenkasse and other German health insurers to conclude rebate contracts under §130c SGB V for the drug combination Emtricitabine/Tenofovir Disoproxil/Rilpivirine. The procedure is open continuously until the contract end date (28 February 2027) and all eligible pharmaceutical entrepreneurs with a valid marketing authorization for the drug combination can join on non-negotiable standard terms. No estimated value is published and no exclusivity is granted.

Risiken

Patent expiry or loss of market exclusivity automatically terminates the contract for the affected drug. This may resul...

No guaranteed sales volume or revenue; the rebate contract does not ensure actual prescriptions or market share.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical entrepreneur under §4(18) AMG for the offered drug
  • Must have a valid marketing authorization or be otherwise entitled to market the drug combination
  • Must have registered seat within Germany, EU, or EEA

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open House Original Rebate Contracts 2025-05 - Emtricitabine/Tenofovir Disoproxil/Rilpivirine (Active Combination)

The objective is to conclude rebate contracts with all eligible pharmaceutical entrepreneurs for the drug combination Emtricitabine/Tenofovir Disoproxil/Rilpivirine under uniform, non-negotiable conditions. The contract runs from 1 March 2025 to 28 February 2027 (max. 24 months), but ends automatically upon patent expiry or loss of market exclusivity.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Feb 2025 - Feb 2027

Kategorie

Pharmaceutical products

Frist

Deadline Feb 27, 2027

Vergabedetails

Veröffentlichungsdatum
20 Jan 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
40386-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3